SEC Form 4 · accession 0001179110-16-017498
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Athena Countouriotis
Officer — SVP and Chief Medical Officer
Period of report
Jan 5, 2016
Accepted (ET)
Jan 7, 2016 · 5:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 5, 2016 | M | 7,500 | $0.00 | A | 16,895 | D | |
| Common StockF1 | Jan 5, 2016 | F | 3,257 | $16.39 | D | 13,638 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Jan 5, 2016 | M | 7,500 | D | — | — | Common Stock | 7,500 | 22,500 | D |
Explanation of responses
- F1The reported disposition of 3,257 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements.
- F2This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer.